Spero Therapeutics
Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections.
Launch date
Employees
Market cap
CAD101m
Enterprise valuation
CAD21m (Public information from Sep 2024)
Share price
$1.34 SPRO
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 9.3m | 18.3m | 48.6m | 96.7m | 26.1m | 18.7m | 18.8m |
| % growth | 97 % | 96 % | 166 % | 99 % | (73 %) | (29 %) | - |
| EBITDA | (79.1m) | (87.4m) | (18.9m) | 31.1m | - | - | - |
| % EBITDA margin | (848 %) | (479 %) | (39 %) | 32 % | - | - | - |
| Profit | (78.3m) | (89.8m) | (46.4m) | 22.8m | (86.8m) | (102m) | (89.7m) |
| % profit margin | (839 %) | (492 %) | (96 %) | 24 % | (332 %) | (549 %) | (479 %) |
| EV / revenue | 42.9x | 20.3x | 1.8x | 0.8x | 2.8x | 4.0x | 4.0x |
| EV / EBITDA | -5.1x | -4.3x | -4.7x | 2.5x | - | - | - |
| R&D budget | 67.0m | 64.5m | 47.6m | 51.4m | - | - | - |
| R&D % of revenue | 718 % | 353 % | 98 % | 53 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Seed | ||
$3.0m | Series A | ||
N/A | Seed | ||
$30.0m | Series A | ||
$30.0m | Series B | ||
$6.8m | Grant | ||
$51.7m | Series C | ||
| N/A | $77.0m | IPO | |
| N/A | $75.0m | Post IPO Equity | |
$5.9m | Grant | ||
$125m | Post IPO Equity | ||
$12.9m | Grant | ||
* | $9.0m | Post IPO Equity | |
| Total Funding | CAD191m | ||
Related Content
Recent News about Spero Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.